Andrei Osterman, Ph.D.

Andrei Osterman headshot

Andrei Osterman, Ph.D.

Associate Dean of Curriculum, Graduate School of Biomedical Sciences

Fax: (858) 795-5249

Research Assistant Professor(s)

Andrei Osterman's Research Focus

Breast Cancer, Infectious Diseases, Skin Cancer and Melanoma, Radiation Damage, Cancer

The main focus of Dr. Osterman’s research team is on fundamental and applied aspects of the key metabolic subsystems in a variety of species, from bacteria to human. This group uses a systems biology approach to reconstruct and explore metabolic and transcriptional regulatory networks. This approach combines comparative genomics and other bioinformatic techniques with biochemical and genetic experiments for pathway, gene and target discovery. Using this approach this group predicted and experimentally verified numerous enzyme families in the metabolism of cofactors, carbohydrates, and amino acids. Recent breakthroughs included prediction and characterization of novel transporters, transcriptional regulators and carbohydrate utilization pathways in a number of model bacterial systems. Applications in the field of infectious disease include identification of novel drug targets and structure-based development of novel anti-infective agents. New directions in cancer research are based on application of metabolic profiling technology for identification of novel diagnostic and therapeutic targets. Other directions of the on-going research include bioinformatics of regulatory proteolysis and applications of structural modeling for exploration of metabolic networks and gene discovery.

Andrei Osterman's Bio

Andrei Osterman is a Professor in the Immunity and Pathogenesis Program Program at the Infectious and Inflammatory Disease Center of Sanford Burnham Prebys Medical Discovery Institute (since August 2003). He received his doctorate from Moscow State University in 1983, did postdoctoral work UT Southwestern Medical Center, and held the position of the Director and then Vice President of Research at Integrated Genomics in 1999-2003. Dr. Osterman is one of the founders of the Fellowship for Interpretation of Genomes (FIG), a nonprofit research organization that launched the Project to Annotate 1,000 Genomes in 2003. FIG provides the open-source integration of all publicly available genomes and tools for their comparative analysis, annotation, and metabolic reconstruction.


bioinformatics

Publications

Functional specialization in proline biosynthesis of melanoma.

De Ingeniis J, Ratnikov B, Richardson AD, Scott DA, Aza-Blanc P, De SK, Kazanov M, Pellecchia M, Ronai Z, Osterman AL, Smith JW

PLoS One 2012 ;7(9):e45190

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.

Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW

Pigment Cell Melanoma Res 2012 May ;25(3):375-83

Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect.

Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW

J Biol Chem 2011 Dec 9 ;286(49):42626-42634

Show All Select Publications

Evaluating microbiome-directed fibre snacks in gnotobiotic mice and humans.

Delannoy-Bruno O, Desai C, Raman AS, Chen RY, Hibberd MC, Cheng J, Han N, Castillo JJ, Couture G, Lebrilla CB, Barve RA, Lombard V, Henrissat B, Leyn SA, Rodionov DA, Osterman AL, Hayashi DK, Meynier A, Vinoy S, Kirbach K, Wilmot T, Heath AC, Klein S, Barratt MJ, Gordon JI

Nature 2021 Jul ;595(7865):91-95

Shared and Unique Evolutionary Trajectories to Ciprofloxacin Resistance in Gram-Negative Bacterial Pathogens.

Zlamal JE, Leyn SA, Iyer M, Elane ML, Wong NA, Wamsley JW, Vercruysse M, Garcia-Alcalde F, Osterman AL

mBio 2021 Jun 29 ;12(3):e0098721

Binary Metabolic Phenotypes and Phenotype Diversity Metrics for the Functional Characterization of Microbial Communities.

Iablokov SN, Novichkov PS, Osterman AL, Rodionov DA

Front Microbiol 2021 ;12:653314

The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.

Giblin W, Bringman-Rodenbarger L, Guo AH, Kumar S, Monovich AC, Mostafa AM, Skinner ME, Azar M, Mady AS, Chung CH, Kadambi N, Melong KA, Lee HJ, Zhang L, Sajjakulnukit P, Trefely S, Varner EL, Iyer S, Wang M, Wilmott JS, Soyer HP, Sturm RA, Pritchard AL, Andea AA, Scolyer RA, Stark MS, Scott DA, Fullen DR, Bosenberg MW, Chandrasekaran S, Nikolovska-Coleska Z, Verhaegen ME, Snyder NW, Rivera MN, Osterman AL, Lyssiotis CA, Lombard DB

J Clin Invest 2021 Jun 15 ;131(12)

Experimental evolution in morbidostat reveals converging genomic trajectories on the path to triclosan resistance.

Leyn SA, Zlamal JE, Kurnasov OV, Li X, Elane M, Myjak L, Godzik M, de Crecy A, Garcia-Alcalde F, Ebeling M, Osterman AL

Microb Genom 2021 May ;7(5)

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications.

Mett V, Kurnasov OV, Bespalov IA, Molodtsov I, Brackett CM, Burdelya LG, Purmal AA, Gleiberman AS, Toshkov IA, Burkhart CA, Kogan YN, Andrianova EL, Gudkov AV, Osterman AL

Commun Biol 2021 Apr 12 ;4(1):466

Show All Publications